Copyright
©The Author(s) 2025.
World J Gastroenterol. Jul 14, 2025; 31(26): 109285
Published online Jul 14, 2025. doi: 10.3748/wjg.v31.i26.109285
Published online Jul 14, 2025. doi: 10.3748/wjg.v31.i26.109285
Figure 3 Dynamic changes in lipid profiles between the tenofovir amibufenamide group and the tenofovir disoproxil fumarate group in chronic hepatitis B.
A-E: The two groups exhibited comparable virological performance regarding cholesterol (A), low-density lipoprotein (B), high-density lipoprotein (C), triglycerides (D) and the triglycerides/high-density lipoprotein ratio (E). TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; CHOL: Cholesterol; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; TG: Triglycerides; TC: Total cholesterol.
- Citation: Zeng ZH, Liu JQ, Zhang M, Qiu CL, Xu ZY. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. World J Gastroenterol 2025; 31(26): 109285
- URL: https://www.wjgnet.com/1007-9327/full/v31/i26/109285.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i26.109285